- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01582867
HemoControl System Activated in Hemodiafiltration Treatments (SOCRATHE)
Studio Cross-Over Controllato Randomizzato Sul Dispositivo ArTis Con Hemocontrol in Emodiafiltrazione - SOCRATHE
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hemodiafiltration (HDF) is a dialysis technique that allows the removal of high molecular weight toxic solutes exploiting the convective transport through the dialyzer membrane: at the same time, the HDF has a positive impact on the systemic hemodynamic, ameliorating in this way the tolerance of the treatment. Unfortunately, also the HDF therapy can be not well tolerated, introducing in the patients serious hypovolemia during the removal of the body water accumulated in the interdialytic period.
The HemoControl system, automatically controlling the relative blood volume change of the patient, avoids the onset of the hypovolemia. Today the HemoControl system can be used only during conventional hemodialysis treatments; the objective of this study is to combine the advantages of the intradialytic hemodynamic stabilization achievable by means of HemoControl with the inherent advantages, both of depurative and cardiovascular kind, typical of the Hemodiafiltration technique.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
(bo)
-
Bologna, (bo), Italy, 40138
- Policlinico Sant'Orsola Malpighi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A subject must meet ALL of the following inclusion criteria in order to participate in this study:
- ESRD in chronic dialysis treatments for at least 3 months
- Age ≥ 18 years
- Body weight ≥ 40 kg
- Blood flow rate ≥ 250 ml/min with a recirculation of the vascular access < 5%
- Use of not fractioned heparin in continuous infusion as anticoagulant
- Stable anticoagulation dosage over the last 6 treatments
- Stable dialysis prescription (Qb, Qd, treatment time) over the last 6 treatments
- Informed consent for participating to the study
- Stable Haemoglobin concentration at beginning of the treatment lower than or equal to 14 g/dl.
Exclusion Criteria:
A subject shall NOT participate in the study if he/she meets ANY of the following criteria:
- HIV positivity
- Active Hepatitis A, B or C
- Pregnancy
- Participating in other clinical investigations during the course of this study
- Failed to release consent
- Known coagulation disorders (clotting problems)
- Known bleeding risk
- Clinical or laboratory diagnosis of acute infection
- Recent (last 4 weeks) surgical intervention
- Therapy prescribed is only HD, HF or isolated UF mode
- Active phase cancer,
- Active phase immune disease.
- Serious hemostasis disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HD and HDF
During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks.
Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
|
Software versions: Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01
Other Names:
|
Experimental: HDF and HD
patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
|
Software versions: Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sodium mass balance
Time Frame: during dialysis treatment within 18 weeks
|
|
during dialysis treatment within 18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
blood pressure
Time Frame: Pre-dialytic within 18 weeks
|
difference between the pre-treatment systolic and diastolic blood pressures in On-Line Hemodiafiltration (HDF) and hemodialysis (HD) with respect to the control treatments
|
Pre-dialytic within 18 weeks
|
thirst perception
Time Frame: during dialysis within 18 weeks
|
Average difference between the thirst score reported by the patient during On-Line Hemodiafiltration (HDF) and hemodialysis (HD) treatments with respect to the score reported during the control treatments
|
during dialysis within 18 weeks
|
weight gain
Time Frame: between dialysis treatments within 18 weeks
|
difference between the interdialytic weight gain in On-Line Hemodiafiltration (HDF) and hemodialysis (HD) treatments with respect to the control treatment
|
between dialysis treatments within 18 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Antonio Santoro, Dr., Policlinico Sant'Orsola Malpighi
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1495 (Other Identifier: CSL Behring)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
Washington University School of MedicineCompletedAcute Renal Failure | Chronic Renal FailureUnited States
-
University Hospital, Clermont-FerrandRecruitingAcute Kidney Injury | Transient Acute Renal Failure | Persistent Acute Renal FailureFrance
-
University Hospital, GhentCompletedAcute Renal Failure | Chronic Renal FailureBelgium
-
The University of Hong KongHospital Authority, Hong KongCompletedEnd-stage Renal Failure (ESRF)Hong Kong
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
Clinical Trials on ARTIS hemodialysis system
-
Baxter Healthcare CorporationCompleted
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
Outset MedicalCompleted
-
Quanta Dialysis Technologies LtdActive, not recruiting
-
Ullevaal University HospitalCompleted
-
Outset MedicalRecruiting
-
Qidni Labs Inc.RecruitingKidney Disease, End-StageCanada
-
Deka Research and DevelopmentCVS Kidney Care LLC.CompletedEnd Stage Renal DiseaseUnited States
-
Deka Research and DevelopmentCVS Kidney Care LLC.CompletedEnd-Stage Renal DiseaseUnited States
-
Beaumont HospitalBaxter Healthcare CorporationUnknownSleep Disorders | Renal Failure Chronic Requiring HemodialysisIreland